Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

627 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity.
Dash R, Bhutia SK, Azab B, Su ZZ, Quinn BA, Kegelmen TP, Das SK, Kim K, Lee SG, Park MA, Yacoub A, Rahmani M, Emdad L, Dmitriev IP, Wang XY, Sarkar D, Grant S, Dent P, Curiel DT, Fisher PB. Dash R, et al. Among authors: dent p. Cytokine Growth Factor Rev. 2010 Oct;21(5):381-91. doi: 10.1016/j.cytogfr.2010.08.004. Cytokine Growth Factor Rev. 2010. PMID: 20926331 Free PMC article. Review.
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, Pellecchia M, Reed JC, Sarkar D, Fisher PB. Dash R, et al. Among authors: dent p. Proc Natl Acad Sci U S A. 2011 May 24;108(21):8785-90. doi: 10.1073/pnas.1100769108. Epub 2011 May 9. Proc Natl Acad Sci U S A. 2011. PMID: 21555592 Free PMC article.
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.
Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA, Sarkar S, Wang XY, Hedvat M, Dmitriev IP, Curiel DT, Grant S, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Azab B, et al. Among authors: dent p. J Cell Physiol. 2012 May;227(5):2145-53. doi: 10.1002/jcp.22947. J Cell Physiol. 2012. PMID: 21780116 Free PMC article.
Targeting Mcl-1 for the therapy of cancer.
Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, Wu B, Stebbins JL, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Quinn BA, et al. Among authors: dent p. Expert Opin Investig Drugs. 2011 Oct;20(10):1397-411. doi: 10.1517/13543784.2011.609167. Epub 2011 Aug 19. Expert Opin Investig Drugs. 2011. PMID: 21851287 Free PMC article. Review.
Targeting the Bcl-2 family for cancer therapy.
Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB. Thomas S, et al. Among authors: dent p. Expert Opin Ther Targets. 2013 Jan;17(1):61-75. doi: 10.1517/14728222.2013.733001. Epub 2012 Nov 22. Expert Opin Ther Targets. 2013. PMID: 23173842 Free PMC article. Review.
627 results